All News
Turning the Corner on CV Risk in Rheumatoid Arthritis
Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.
Read Article
GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at week 24 had greater C1M reduction than non-responder. Abstract #POS1036 #EULAR2021 @RheumNow https://t.co/4JqbaMexuR https://t.co/gXltKn6qIc
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021 PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting.
https://t.co/sUXTXDXrFh https://t.co/tQZktnlUXj
Links:
Dr. John Cush RheumNow ( View Tweet)
What's your EULAR IQ? #EULAR2021
https://t.co/psumBpzUc7 https://t.co/ZyD87VY8u6
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 - Day 1 Podcasts
Check out this compilation of our EULAR 2021 Day 1 broadcasts .
You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/p6n7BTsK5C https://t.co/I36SMGlb2o
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: EULAR 2021 – Day 1 Report #EULAR2021
https://t.co/igpQYMkf9l https://t.co/qESsN3meJe
Links:
Dr. John Cush RheumNow ( View Tweet)
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson
Dr. Yusof interviews Dr. Robinson about abstract OP0013, presented at the virtual #EULAR2021 meeting.
https://t.co/IPe6lMM7NQ
Links:
Dr. John Cush RheumNow ( View Tweet)
How common is RA ILD? @RheumNow #EULAR2021 @eular_org
Janet Pope Janetbirdope ( View Tweet)
RA ILD is NOT a needle in a haystack! Older age& makes & COPD is a risk MUC5B gene SNIP are risks NOT ACPA. 7-10% will have relevant RA ILD. Are you ready to identity & treat it? @RheumNow #EULAR2021 BI RA ILD symposium @eular_org https://t.co/4mS6Jejjqk
Janet Pope Janetbirdope ( View Tweet)
Glad to present my own work in the irAE session #EULAR2021
PET/CT can help show us that PMR irAEs are a distinct phenomenon, not just generalised immune activation...
and if we can understand PMR irAEs maybe we can understand a bit about classical PMR as well!
OP0194 @RheumNow https://t.co/d4yjExjES3
David Liew drdavidliew ( View Tweet)
Leave my MTX alone says pt & #rheumatologist if pt has chronic ILD. Acute pneumonia from MTX is NOT chronic ILD in RA @RheumNow @eular_org #EULAR2021 #BoehringerIngelheim RA ILD silent killer symposium https://t.co/IQTINuUpVq
Janet Pope Janetbirdope ( View Tweet)
#POS0196 1 year results of the SELECT-PsA 2 study: Inadequate responders to ≥1bDMARD subjected to #upadacitinib maintained efficacy throughout week 56 (74% of pts completed 1-year)
#EULAR2021 @RheumNow https://t.co/xpqhzgeI6q
Paul Studenic Stiddyo ( View Tweet)
Complements that are low in #SLE pregnancy have POORER fetal outcomes. What happens to C3 & C4 in pregnancy? They should ⬆️ by 28% C3, 11% C4 in 1st Trimester @RheumNow #EULAR2021 POS0103. So order C3&C4 early in pregnancy in SLE & follow! https://t.co/FpHHj74e43
Janet Pope Janetbirdope ( View Tweet)
Great talks on comorbidities in RA at #EULAR2021 today. What do we struggle most with in RA management? @RheumNow
Richard Conway RichardPAConway ( View Tweet)
Can well controlled SLE pt taper #Belimumab? Maybe. Single site w 48 pts & over 2 yrs 44% could taper esp if on #plaquenil. This may change my practice but will follow pts closely POS0107 @RheumNow #EULAR2021 @eular_org https://t.co/8WCrt11ubV
Janet Pope Janetbirdope ( View Tweet)
Check out our psoriatic arthritis coverage from #EULAR2021. Head to RheumNow for full EULAR coverage.
https://t.co/NzB2e2Vfwb
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021.
“SpA” talk by Prof. Désirée van der Heijde.
Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏
/TK https://t.co/JFr3VC8sXY
ARD & RMD Open ARD_BMJ ( View Tweet)
Novel MOA Rx SLE skin #OP0132
Iberdomide: high affinity cereblon ligand ➡️proteasomal degradation of Ikaros&Aiolos
- works for SCLE & CCLE
- works early 4 wks, cont improves at 24 wks
- high PCB resp wk 24, CLASI nonsig
- dose dept AE's ⬇️WBC, infx, rash #EULAR2021 @rheumnow https://t.co/wYLdAZLvJq
k dao KDAO2011 ( View Tweet)